Skip to content
Screener

Cogent Biosciences, Inc. COGT Q1 2026 earnings

Reported May 5, 2026 · Before market open

EPS-$0.53In line
Revenue estimate$500.0
EPS estimate-$0.53

Next report

Aug 10, 2026 (In 3 days)
Revenue estimate$1.0K
EPS estimate-$0.55

Financials

Q1 2026

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation & ratios

Valuation

as of 08/06/26
See full
Market cap$7.22B+371%
Enterprise value$7B+377%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity0×-0.1×
Current ratio15.1×+10.0×

FAQ

When did Cogent Biosciences, Inc. report Q1 2026 earnings?
Cogent Biosciences, Inc. (COGT) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Cogent Biosciences, Inc.'s Q1 2026 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.53 for Q1 2026.
Did Cogent Biosciences, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.53 by $0.00.
How did Cogent Biosciences, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 1.9% from $-0.52.
Where can I find Cogent Biosciences, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-205124) and the 10-Q periodic report (0001193125-26-205170) directly on SEC EDGAR. The filing index links above go to sec.gov.